GVHD
Clinical trials for GVHD explained in plain language.
Never miss a new study
Get alerted when new GVHD trials appear
Sign up with your email to follow new studies for GVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in controlling transplant complications
Disease control CompletedThis study tested a new drug called EQ001 in 30 people who developed acute graft-versus-host disease (aGVHD) after a stem cell transplant. aGVHD is a serious condition where donor immune cells attack the patient's body. The goal was to see if EQ001 is safe and can help control th…
Matched conditions: GVHD
Phase: PHASE1, PHASE2 • Sponsor: Biocon Limited • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…
Matched conditions: GVHD
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control CompletedThis study tested whether adding pacritinib to standard immune-suppressing drugs (sirolimus and tacrolimus) could prevent graft-versus-host disease (GVHD) in 40 patients receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the recipient's …
Matched conditions: GVHD
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo may reduce chronic transplant complications in blood cancer patients
Disease control CompletedThis study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: Dimitrios Tzachanis, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug cocktail aims to stop transplant rejection
Prevention CompletedThis phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Simple blood count may forecast deadly transplant complication
Knowledge-focused CompletedThis study looked at whether counting a specific type of cell in the blood (circulating endothelial cells) can predict the risk of acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant for blood cancer. Researchers measured these cells before transplan…
Matched conditions: GVHD
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Scientists test designer immune molecules in autoimmune diseases
Knowledge-focused CompletedThis study looked at whether specially engineered versions of a natural immune protein (IL-2) can selectively boost regulatory T cells, which help calm the immune system. Researchers took blood samples from 67 people with various autoimmune or inflammatory conditions and tested t…
Matched conditions: GVHD
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC